Ascendis Pharma A/S (ASND) Financials

ASND Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 2.6 billion 969.1 million
March 31, 2026 2.3 billion 1.7 billion
Dec. 31, 2025 1.5 billion 1.7 billion
Sept. 30, 2025 1.4 billion 1.6 billion

ASND Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 323.1 million ?
March 31, 2026 -18.0 million 34.8 million
Dec. 31, 2025 79.1 million 35.2 million
Sept. 30, 2025 2.5 million 36.0 million

ASND Net Income

No data available :(

ASND Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 926.6 million 438.8 million -
March 31, 2026 657.1 million 442.9 million -
Dec. 31, 2025 722.9 million 452.1 million -
Sept. 30, 2025 632.6 million 388.9 million -

ASND Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 78.0 million
March 31, 2026 73.9 million
Dec. 31, 2025 72.1 million
Sept. 30, 2025 71.6 million

ASND Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 3.7 million 85.2 million 199.2 million -
March 31, 2026 9.0 million 66.0 million 167.5 million -
Dec. 31, 2025 3.9 million 88.0 million 156.4 million -
Sept. 30, 2025 62197 78.5 million 131.1 million -

ASND Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 393.6 million 36.9 million
March 31, 2026 287.2 million 24.8 million
Dec. 31, 2025 287.8 million 31.9 million
Sept. 30, 2025 250.7 million 26.2 million

ASND

Price: $226.50

52 week price:
186.05
282.15

Earnings Per Share: 12.96 USD

P/E Ratio: 19.20

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: Denmark

Volume: 126716

Ebitda: -36.5 million

Market Capitalization: 16.8 billion

Links: